Compare IRM & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IRM | NTRA |
|---|---|---|
| Founded | 1951 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical Specialities |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0B | 27.0B |
| IPO Year | 1996 | 2015 |
| Metric | IRM | NTRA |
|---|---|---|
| Price | $84.63 | $244.06 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | $114.80 | ★ $227.69 |
| AVG Volume (30 Days) | ★ 2.5M | 1.7M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | ★ 4.10% | N/A |
| EPS Growth | ★ 50.78 | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $6,639,849,000.00 | $2,116,676,000.00 |
| Revenue This Year | $12.70 | $32.77 |
| Revenue Next Year | $10.62 | $16.51 |
| P/E Ratio | $156.47 | ★ N/A |
| Revenue Growth | 10.88 | ★ 38.17 |
| 52 Week Low | $72.33 | $125.38 |
| 52 Week High | $121.00 | $245.59 |
| Indicator | IRM | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 32.90 | 80.03 |
| Support Level | $82.00 | $233.67 |
| Resistance Level | $86.93 | $240.18 |
| Average True Range (ATR) | 3.06 | 7.39 |
| MACD | 0.02 | 0.68 |
| Stochastic Oscillator | 22.34 | 97.49 |
Iron Mountain Inc is a record management services provider. It is organized as a REIT. Majority of its revenue comes from its storage business, with the rest coming from value-added services. The firm caters to enterprise clients in developed markets. Its business segments include Global RIM Business; Global Data Center Business; and Corporate and Other Business. It generates maximum revenue from the Global RIM Business segment.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.